Efficacy, Immunogenicity and Safety of COVID-19 Vaccine , Inactivated in Children and Adolescents
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase Ⅲ Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of COVID-19 Vaccine(Vero Cell) ,Inactivated in Children and Adolescents Aged 6 Months to 17 Years
Sponsor: Sinovac Research and Development Co., Ltd.
Listed as NCT04992260, this PHASE3 trial focuses on COVID-19 and remains completed. Sponsored by Sinovac Research and Development Co., Ltd., it has been updated 10 times since 2021, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Nov 2023 — Jul 2024 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Feb 2023 — Nov 2023 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
▶ Show 5 earlier versions
-
Sep 2022 — Feb 2023 [monthly]
Recruiting PHASE3
-
Jan 2022 — Sep 2022 [monthly]
Recruiting PHASE3
-
Dec 2021 — Jan 2022 [monthly]
Recruiting PHASE3
-
Oct 2021 — Dec 2021 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Sep 2021 — Oct 2021 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Sinovac Research and Development Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .